Clinical trial
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788 is registered in ClinicalTrials.gov with Guangzhou Bio-gene Technology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Lead sponsor
- Guangzhou Bio-gene Technology Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 7, 2024
- Completion date
- July 31, 2027
- Enrollment
- 24 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.